496 related articles for article (PubMed ID: 25542869)
1. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Rolón MJ; Figueroa MI; Sued O; Cahn P
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
[TBL] [Abstract][Full Text] [Related]
2. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
3. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
4. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
Aguirrebengoa K
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
[TBL] [Abstract][Full Text] [Related]
5. [Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
Sebastián Mde L; Pardo OB; Ortega FP
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():12-7. PubMed ID: 25542870
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
Zamora L; Gatell JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():2-6. PubMed ID: 25542868
[TBL] [Abstract][Full Text] [Related]
8. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
10. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Tasias M; Aldeguer JL
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
[TBL] [Abstract][Full Text] [Related]
11. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA
PLoS One; 2015; 10(2):e0118228. PubMed ID: 25723472
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.
Kanters S; Socias ME; Paton NI; Vitoria M; Doherty M; Ayers D; Popoff E; Chan K; Cooper DA; Wiens MO; Calmy A; Ford N; Nsanzimana S; Mills EJ
Lancet HIV; 2017 Oct; 4(10):e433-e441. PubMed ID: 28784426
[TBL] [Abstract][Full Text] [Related]
15. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
16. State of the Art of Dual Therapy in 2015.
Nozza S; Svicher V; Saracino A; d'Ettorre G; De Luca A; Maggiolo F; Bonora S; di Biagio A; Rusconi S; Mussini C
AIDS Rev; 2015; 17(3):127-34. PubMed ID: 26450801
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Eholie SP; Ekouevi DK; Chazallon C; Charpentier C; Messou E; Diallo Z; Zoungrana J; Minga A; Ngom Gueye NF; Hawerlander D; Dembele F; Colin G; Tchounga B; Karcher S; Le Carrou J; Tchabert-Guié A; Toni TD; Ouédraogo AS; Bado G; Toure Kane C; Seydi M; Poda A; Mensah E; Diallo I; Drabo YJ; Anglaret X; Brun-Vezinet F;
Lancet HIV; 2024 Jun; 11(6):e380-e388. PubMed ID: 38740027
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI;
Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
[TBL] [Abstract][Full Text] [Related]
20. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]